1. Japan Stocks

  2. •

    Healthcare

  3. •

    Medical - Distribution
MediPal Holdings Corporation

MediPal Holdings Corporation

MEPDF
MediPal Holdings CorporationUS flagOther OTC
18.35
USD
- -
- -
3.76BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
13,042.86
12,701.33
13,373.23
13,531.42
13,942.84
14,269.53
15,062.49
15,293.99
15,673.89
16,002.93
16,803.45
17,609.69
- -
8,487.76
Basic EPS, GAAP
112.76
104.72
135.89
128.12
154.13
154.08
175.8
113.95
140.13
184.82
195.83
193.2
- -
115.98
Free Cash Flow per Basic Share
-109.8
288.69
-72.47
53.51
146.49
202.81
136.89
89.44
201.65
12.58
200.43
230.85
- -
- -
Dividend per Share
21.98
23.99
25
30
32
36.11
40.04
42
42
46
52.78
60.14
- -
- -
Book Value per Share
991.98
1,063.79
1,172.28
1,276.32
1,400.89
1,541.07
1,726.87
1,846.46
1,943.25
2,081.9
2,180.09
2,328.57
- -
2,256.14
Tangible Book Value per Share
1,762.8
1,975.58
2,102.12
2,244.82
2,471.61
2,595.45
2,761.34
2,994.57
3,043.97
3,086.51
3,293.89
3,444.15
- -
3,418.61
Basic Weighted Avg Shares
226
226
226
226
226
223
216
210
210
210
212
208
206
210
Sales/Revenue/Turnover
2,947,738
2,872,913
3,028,235
3,064,041
3,146,341
3,181,935
3,253,122
3,211,173
3,290,921
3,360,008
3,558,732
3,671,328
- -
1,779,743
Operating Margin (%)
1.18
1.14
1.4
1.29
1.41
1.57
1.63
1.2
1.39
1.46
1.33
1.51
- -
1.5
Depreciation Expense
13,147
12,325
12,459
13,794
15,374
13,928
14,687
14,792
14,338
14,648
17,982
18,417
- -
7,043
Net Income, GAAP
25,485
23,687
30,771
29,011
34,780
34,359
37,968
23,926
29,423
38,806
41,474
40,279
- -
24,320
Effective Tax Rate (%)
37.93
35.22
32.63
30.72
31.4
28.42
32.18
31.73
31.57
31.03
30.74
32.84
- -
30.23
Profit Margin (%)
0.86
0.82
1.02
0.95
1.11
1.08
1.17
0.75
0.89
1.15
1.17
1.1
- -
1.37
Working Capital
133,724
150,912
159,158
166,901
193,802
202,785
200,579
221,278
200,950
207,761
236,471
273,299
- -
244,525
LT Debt
8,832
4,928
12,150
15,464
39,927
34,437
30,728
30,228
- -
- -
- -
- -
- -
- -
Total Equity
407,480
457,604
488,328
521,165
572,656
592,848
607,424
638,933
649,089
688,055
736,612
757,947
- -
757,655
Return on Invested Capital (%)
4.84
4.49
5.49
5.02
5.09
5.54
5.54
3.96
4.56
4.85
4.52
4.91
- -
2.47
Return on Capital (%)
6.78
5.6
6.95
5.65
6.12
4.97
4.98
2.72
3.6
5.23
5.37
4.75
- -
3.25
Return on Common Equity (%)
11.92
10.19
12.16
10.46
11.49
10.42
10.6
6.29
7.4
9.18
9.23
8.51
- -
5.27

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
210
- -
208
Market Capitalization
- -
- -
399,053

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
1,244,190
- -
1,306,803
Cash, Cash Equivalents & STI
230,470
- -
251,385
Accounts Receivable, Net
758,084
- -
771,809
Inventories
172,030
- -
197,578
Total Current Liabilities
1,007,719
- -
1,062,278
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
886,737
892,252
935,926
843,817
3,558,732
2025
- -
- -
- -
- -
3,671,328
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
52.32
- -
- -
- -
195.83
2025
- -
- -
- -
- -
193.2
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
52.78
2025
- -
- -
- -
- -
60.14
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Shuichi Watanabe
Full Time Employees
13,075
Sector
Healthcare
Industry
Medical - Distribution
Address
2-7-15, Yaesu Tokyo Japan 104-8461
IPO Date
Feb 22, 2019
Website
medipal.co.jp
Similar Companies
Sinopharm Group Co. Ltd. (SHTDY)
Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY)
Sinopharm Group Co. Ltd. (1099.HK)
EBOS Group Limited (EBO.AX)
Paragon Care Limited (PGC.AX)
Wellgistics Health, Inc. (WGRX)
Business
MediPal Holdings Corporation MediPal Holdings Corporation (TSE: 7459), founded in 1898 and headquartered in Tokyo, Japan, operates as a holding company overseeing the wholesale distribution of pharmaceuticals, healthcare products, cosmetics, daily necessities, and animal health items across Japan through a network of over 300 bases from Hokkaido to Okinawa. Its core segments encompass the Prescription Pharmaceutical Wholesale Business, conducted via subsidiaries including MEDICEO Corporation, EVERLTH Co., Ltd., ATOL Co., Ltd., TOSHICHI Co., Ltd., SPLine Corporation, MM Corporation, ASTEC Co., Ltd., PharField Corporation, MEDIE Co., Ltd., PreMedica Inc., FloraDiscovery Inc., MIC Co., Ltd., Medipal Insurance Service, PRESUSCUBE Corporation, MEDISKET Corporation, and Kachidoki Yakuhin, which procures and delivers prescription drugs, medical equipment, materials, clinical diagnostic reagents, and related healthcare products to hospitals, clinics, and dispensing pharmacies; the Cosmetics, Daily Necessities and OTC Pharmaceutical Wholesale Business, led by PALTAC Corporation, supplying beauty, health, and over-the-counter products to drugstores, home centers, convenience stores, and supermarkets with services like in-store merchandising, product composition analysis, shelf allocation, inventory management, and handling of new or discontinued items; and the Animal Health Products and Food Processing Raw Materials Wholesale Business, managed by MP AGRO Co., Ltd. and MP Gokyo Food & Chemical Co., Ltd., distributing veterinary products to animal hospitals, farms, and cooperatives alongside raw materials and additives to food processors. Recent developments include the acquisition of PRESUSCUBE Corporation as a subsidiary in April 2023 with additional investment in July 2024 to enhance digital transformation support for insurance pharmacies via tools like BHI management analysis and PRESUS business systems, leveraging MEDIPAL's logistics and sales resources; full ownership of Toshichi Inc. in April 2023, PreMedica Inc. and FloraDiscovery Inc. in May 2024, and Sumitomo Pharma Food & Chemical Co., Ltd. (now MP Gokyo Food & Chemical) in March 2023; a global licensing and co-development agreement with JCR Pharmaceuticals in September 2025 for JR-479, expanding on prior ultra-rare disease collaborations including JR-471 and JR-446 since 2022; the launch of a group brand website and official social media accounts in January 2025; and active pursuit of mergers and acquisitions in 2025 to diversify amid shrinking drug margins, alongside the April 2025 merger of MVC Co., Ltd. into ATOL Co., Ltd.